CRB-701 for Throat Cancer

(TEMPO-1 Trial)

This trial tests whether a new drug, CRB-701, can treat throat cancer that has returned or spread after previous treatments. CRB-701 is a specialized chemotherapy designed to target cancer cells more precisely. Researchers aim to evaluate its effectiveness compared to standard medicines and assess its safety and impact on quality of life. Individuals with throat cancer affecting the tonsils or throat, who have already undergone chemotherapy and immunotherapy, might be suitable candidates. Participants will visit a clinic every three weeks for treatment and undergo regular scans to monitor progress. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

A previous study found CRB-701 to be generally safe and well-tolerated. Fewer than 3% of patients stopped treatment due to side effects. Common side effects included eye inflammation, tiredness, hair loss, changes in taste, and low red blood cell count. This safety profile remained consistent across various cancer types, including head and neck cancers. Thus far, CRB-701 appears to be a promising option with manageable side effects.¹²³⁴⁵

CRB-701 is unique because it introduces a new approach for treating throat cancer by utilizing an innovative active ingredient that specifically targets cancer cells. Unlike traditional treatments like capecitabine, cetuximab, or docetaxel, which have been the mainstays of care, CRB-701 is administered intravenously every three weeks, potentially offering a more convenient dosing schedule. Researchers are particularly excited about CRB-701 because it has the potential to improve outcomes by directly attacking the cancer cells with precision, which could lead to more effective and potentially fewer side effects compared to existing therapies.

Research has shown that CRB-701, one of the treatments studied in this trial, yields promising results for head and neck cancers, including throat cancer. Previous studies found that nearly half of the patients experienced tumor shrinkage, and patients lived longer without disease progression. CRB-701 is a type of targeted chemotherapy known as an antibody-drug conjugate, which delivers the drug directly to cancer cells, potentially reducing harm to healthy cells. These findings suggest that CRB-701 could effectively treat throat cancer, especially for those unresponsive to treatments like platinum-based chemotherapy or immunotherapy. Participants in this trial may receive CRB-701 or an investigator's choice of capecitabine, cetuximab, or docetaxel as monotherapy.⁶⁷⁸⁹¹⁰